Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan

Table 4 Characteristics of patients potentially not managed well by acute, preventive, or combination treatment

	Total (12 M-F/U population)		Triptan switch Case 1		MOH Case 2		No decrease of acute medication with conventional preventive treatment Case 3-1^a		No decrease of acute medication with Anti-CGRP mAbs treatment Case 3-2^a
	N = 114,931		N = 1,337		N = 4,229		N = 651		N = 62
Percentage (N/Population 2)	100% (114,931/114,931)		1.2% (1,337/114,931)		3.7% (4,229/114,931)		23.0% (651/2,832^b)		29.0% (62/214^c)
Age at the index date (years)
Mean ± SD	39.2 ± 11.4		37.4 ± 10.3		42.3 ± 10.5		40.2 ± 10.2		37.5 ± 8.5
Sex	n	%	n	%	n	%	n	%	n	%
Male	40,935	35.6	356	26.6	1,259	29.8	212	32.6	17	27.4
Female	73,996	64.4	981	73.4	2,970	70.2	439	67.4	45	72.6
Comorbidities during baseline period	n	%	n	%	n	%	n	%	n	%
Total patients	38,044	33.1	396	29.6	2,044	48.3	244	37.5	23	37.1
Cerebrovascular disease	4,061	3.5	32	2.4	194	4.6	32	4.9	2	3.2
Hypertension	10,607	9.2	68	5.1	656	15.5	58	8.9	2	3.2
Ischemic heart diseases	1,838	1.6	13	1.0	106	2.5	11	1.7	1	1.6
Peripheral vascular disease	2,145	1.9	22	1.6	115	2.7	13	2.0	1	1.6
Any of the cardiovascular-related comorbidities listed above	15,453	13.4	121	9.1	871	20.6	96	14.7	5	8.1
Mood (affective) disorders	11,101	9.7	128	9.6	738	17.5	94	14.4	10	16.1
Neurotic, stress-related, and somatoform disorders	15,126	13.2	171	12.8	918	21.7	110	16.9	9	14.5

CGRP Calcitonin gene-related peptide, 12 M-F/U 12 months of follow-up, mAb Monoclonal antibody, MOH Medication-overuse headache, SD Standard deviation
^aNo decrease in average acute care drug prescription for 3 months after the start of preventive treatment
^bThe number of patients who continued conventional preventive treatment at least 3 months
^cThe number of patients who continued anti-CGRP mAb treatment at least 3 months

ISSN: 1129-2377